The recent loss of the only Phase 3 CeD pipeline candidate highlights the unmet need of suitable treatments for a...
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of...
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As...
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
Launch data tracking the market receptivity for Korsuva (Vifor/Cara Therapeutics), Kerendia (Bayer), Lupkynis (Aurinia Pharmaceuticals), and Tarpeyo (Calliditas) unveils gaps...
Recent endorsement of Evrenzo by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further...
Dermatologists are most enthused about the potential utility of the JAK inhibitor class, including Incyte’s Opzelura, AbbVie’s Rinvoq, Pfizer’s ritlecitinib,...
US and EU5 dermatologists report the availability of an oral JAK inhibitor would make a significant change in their treatment...
Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa., June 17, 2022 /PRNewswire/ —With the approvals...
Cross-specialty analysis on CKD and DKD patient management and evolving use of SGLT2 inhibitors shows market may be poised for...
Will the first and only FDA-approved therapy indicated for EoE fill the treatment void expressed by gastroenterologists? EXTON, Pa., June...
Rheumatologists are more likely than PsA-treating dermatologists to cycle TNFs prior to introducing an alternative mechanism of action agent EXTON,...
